What role would MCM have in prostate cancer, either with or without prostate-specific antigen (PSA), the blood test?
Unfortunately, PSA as a diagnostic test for prostate cancer has a very poor diagnostic value. The outcome can give false positive results in up to 60% of all patients. The initial evidence for MCM as an antibody is that it has a very high diagnostic accuracy with a low false positive rate and therefore looks, even in these early stages, promising.
